

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,084	04/07/2006	Mary Collins	M0274.70042US02	7531
23628 7590 08/13/2007 WOLF GREENFIELD & SACKS, P.C. 600 ATLANTIC AVENUE			EXAMINER	
			OUSPENSKI, ILIA I	
BOSTON, MA 02210-2206			ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
	•		08/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/540,084	COLLINS ET AL.			
·Office Action Summary	Examiner	Art Unit			
	ILIA OUSPENSKI	1644			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this communication. C (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 25 Ju					
<i>'</i> —	·				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	03 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>35-51</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 35-51 are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examine	г.				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
See the attached detailed Office action for a list	or the certified copies not receive	ou.			
Attachment(s)	K-7)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) 🔀 Interview Summary Paper No(s)/Mail Da				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal F 6) Other:				

Application/Control Number: 10/540,084

Art Unit: 1644

DETAILED ACTION

Page 2

1. Applicant's Preliminary Amendment, filed on 06/25/2007, is acknowledged.

Claim 1 – 34 has been cancelled.

Claims 35 – 51 have been added.

Claims 35 – 51 are pending.

2. In a telephone interview with the examiner on 08/03/2007, Applicant pointed out that the previous restriction requirement, mailed on 07/05/2007, crossed in the mail with the preliminary amendment of 06/25/2007. The previous restriction requirement does not apply to the claims as amended on 06/25/2007, and is hereby vacated. A new restriction requirement is set forth herein.

Restriction Requirement

3. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

I. Claims 35 – 44 and 46 – 51, drawn to a method of modulating immune response by contacting a lymphocyte with and anti-PD-1 antibody which comprises one of the sequences recited in claim 1.

II. Claim 45, drawn to a method of modulating immune response by contacting a lymphocyte with and anti-PD-1, wherein the antibody is obtained by a method of screening of antibodies specific for PD-1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions of Groups I – IX are deemed to have no special technical feature that defined the contribution over the prior art of WOOD et al. (US Patent No. 6,808,710; of record – cited in the office action mailed on 07/05/2007; see entire document).

Wood et al. teach an anti-PD-1 antibody PD1-17 (e.g. Example 17 at column 86), and as such, anticipate the special technical feature of the instant claims.

Since Applicant's inventions do not contribute a special technical feature when viewed over the prior art, they do not have a single general inventive concept and so lack unity of invention.

Art Unit: 1644

Species Election

5. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

If any one of Groups I or II is elected, applicant is required to elect a species wherein the antibody comprises the sequence or sequences of antibody:

- A. PD1-17,
- B. PD1-28,
- C. PD1-33,
- D. PD1-35, or
- E. PD1-F2.

These species do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features, for the reasons set forth supra.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

6. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Art Unit: 1644

If any one of Groups I or II is elected, applicant is required to elect a species wherein the antibody specifically binds:

- A. human PD-1 (SEQ ID NO:41), or
- B. mouse PD-1 (SEQ ID NO:56).

These species do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features, for the reasons set forth supra.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA OUSPENSKI whose telephone number is 571-272-2920. The examiner can normally be reached on Monday-Friday 9 5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Dlia arspeush

ILIA OUSPENSKI, Ph.D.

Patent Examiner

Art Unit 1644

August 6, 2007